BACKGROUND: Busulfan treatment as a chemotherapeutic agent has been considered an alternative approach in xenograft model because it offers a simple, convenient, effective, and less toxic conditioning regimen. OBJECTIVE AND METHODS: To investigate busulfan effects on the reconstitution of human immune cells and the generation of immune response to foreign antigens, we generated humanized NOD/SCID/IL-2Rγ(null) (NSG) mice conditioned either busulfan or total body irradiation (TBI) with hCD34(+) CB cells. RESULTS: Busulfan resulted in a high survival rate and effective reconstitution of human immune cells including B, T, macrophage, and dendritic cells in humanized NSG mice, compared to that of TBI. Moreover, the humanized NSG mice conditioned busulfan showed effective B cell development and thereby the high production of human antibody against immunized antigen. CONCLUSION: Humanized mice conditioned by busulfan provide a powerful and versatile tool for studying the entire process of human B-lymphocyte development and for producing specific human antibodies.
BACKGROUND:Busulfan treatment as a chemotherapeutic agent has been considered an alternative approach in xenograft model because it offers a simple, convenient, effective, and less toxic conditioning regimen. OBJECTIVE AND METHODS: To investigate busulfan effects on the reconstitution of human immune cells and the generation of immune response to foreign antigens, we generated humanized NOD/SCID/IL-2Rγ(null) (NSG) mice conditioned either busulfan or total body irradiation (TBI) with hCD34(+) CB cells. RESULTS:Busulfan resulted in a high survival rate and effective reconstitution of human immune cells including B, T, macrophage, and dendritic cells in humanized NSG mice, compared to that of TBI. Moreover, the humanized NSG mice conditioned busulfan showed effective B cell development and thereby the high production of human antibody against immunized antigen. CONCLUSION: Humanized mice conditioned by busulfan provide a powerful and versatile tool for studying the entire process of human B-lymphocyte development and for producing specific human antibodies.
Authors: M Sauer; C Zeidler; B Meissner; K Rehe; A Hanke; K Welte; P Lohse; K-W Sykora Journal: Bone Marrow Transplant Date: 2007-01-08 Impact factor: 5.483
Authors: Julie Lang; Margot Kelly; Brian M Freed; Martin D McCarter; Ross M Kedl; Raul M Torres; Roberta Pelanda Journal: J Immunol Date: 2013-01-18 Impact factor: 5.422
Authors: Anja K Wege; Marcus Schmidt; Elke Ueberham; Marvin Ponnath; Olaf Ortmann; Gero Brockhoff; Jörg Lehmann Journal: MAbs Date: 2014-05-08 Impact factor: 5.857
Authors: Melanie C Dispenza; Rebecca A Krier-Burris; Krishan D Chhiba; Bradley J Undem; Piper A Robida; Bruce S Bochner Journal: J Clin Invest Date: 2020-09-01 Impact factor: 14.808
Authors: Qizhen Shi; Erin L Kuether; Yingyu Chen; Jocelyn A Schroeder; Scot A Fahs; Robert R Montgomery Journal: Blood Date: 2013-11-22 Impact factor: 22.113
Authors: Laura Garcia-Perez; Lieke van Roon; Marco W Schilham; Arjan C Lankester; Karin Pike-Overzet; Frank J T Staal Journal: Cells Date: 2021-04-30 Impact factor: 6.600